Royalty Pharma plc Class A Ordinary Shares (RPRX) is a publicly traded Healthcare sector company. As of May 21, 2026, RPRX trades at $53.04 with a market cap of $23.08B and a P/E ratio of 27.85. RPRX moved +1.21% today. Year to date, RPRX is +33.82%; over the trailing twelve months it is +60.35%. Its 52-week range spans $24.05 to $53.47. Analyst consensus is strong buy with an average price target of $59.43. Rallies surfaces RPRX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
7 analysts cover RPRX: 0 strong buy, 7 buy, 0 hold, 0 sell, and 0 strong sell. The consensus rating is strong buy. The average price target is $59.43.
| Metric | Value |
|---|---|
| Price | $53.04 |
| Market Cap | $23.08B |
| P/E Ratio | 27.85 |
| EPS | $1.91 |
| Dividend Yield | 0.23% |
| 52-Week High | $53.47 |
| 52-Week Low | $24.05 |
| Volume | 4.66K |
| Avg Volume | 0 |
| Revenue (TTM) | $2.44B |
| Net Income | $1.36B |
| Gross Margin | 0.00% |
7 analysts cover RPRX: 0 strong buy, 7 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $59.43.